Sorry I did not know about the earlier discussions on buyouts.

Since Hepalink owns 40% of the shares, and they are only a $4 billion or so market cap company, they are highly unlikely to be able to support RVX in its FDA and other journeys.  The logical home of RVX is in a Pfizer kind of beast.

Now if you are Pfizer, would it not be wonderful to get 40+% of the company by talking to just one shareholder?  Kind of makes it harder for a competitor to outbid on the open market.

Anyways...this is all jumping many many guns...let's first get top line data.  Heck, let's get this deal out of the way!